Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
AssigneeRegenLab USA LLC
InventorsAntoine Turzi, Donald Du Toit
Life of this patent
Estimating the term…
Abstract
The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.
Claims17
A sterilized, vacuum-sealed separator tube for preparing a platelet concentrate from whole blood comprising:
- An inlet adapted to introduce whole blood;
- An anticoagulant;
- A non-toxic and non-mutagenic thixotropic gel;
- and
- wherein, when the separator tube is at least partially filled with the whole blood and centrifuged at a force of about 1,500 g up to about 2,000 g for about 3 to about 10 minutes once in a single centrifugation, blood components in the whole blood are separated into a platelet concentrate to be administered without supernatant removal to a patient, and red blood cells, wherein the platelet concentrate contains greater than 400 billion platelets per liter,
- wherein the thixotropic gel forms a barrier between the platelet concentrate and red blood cells.
A sterilized, vacuum-sealed separator tube for preparing a therapeutic platelet concentrate from whole blood comprising:
- An inlet adapted to introduce whole blood;
- An anticoagulant;
- and
- A thixotropic gel;
- wherein, when the separator tube is at least partially filled with the whole blood and centrifuged at a force of about 1,500 g up to about 2,000 g for about 3 to about 10 minutes once in a single centrifugation, blood components in the whole blood are separated into (i) a therapeutic platelet concentrate obtained with supernatant removal and to be administered to a patient, and (ii)red blood cells, wherein the therapeutic platelet concentrate contains greater than about 570 billion platelets per liter and less than about 0.6×1012 red blood cells per liter,
- wherein the thixotropic gel forms a barrier between the platelet concentrate and red blood cells as a result of the centrifugation.
Dependencies are inferred from the claim text.